Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1639-1651

  Rahlff, Janina ^a   Trusch, Maria ^a   Haag, Friedrich ^a   Bacher, Ulrike ^a   Horst, Andrea ^a   Schlüter, Hartmut ^a   Binder, Mascha ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Abnormal protein bands; Anti myeloma immune response; Antigens; Immunofixation; Multiple myeloma; Oligoclonal immunoglobulins

Indexed keywords

ALPHA ENOLASE; ALPHA GLUCOSIDASE; CHAPERONIN 60; CYCLINE; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; MELANOMA ANTIGEN 4; OLIGOCLONAL BAND; PARAPROTEIN; VIMENTIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; UPREGULATION;

ALPHA-GLUCOSIDASES; ANTIGENS, NEOPLASM; BONE MARROW CELLS; CHAPERONIN 60; HUMANS; IMMUNOGLOBULINS; MITOCHONDRIAL PROTEINS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PHOSPHOPYRUVATE HYDRATASE; PROLIFERATING CELL NUCLEAR ANTIGEN; STEM CELL TRANSPLANTATION; UP-REGULATION; VIMENTIN;

EID: 84867582628     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1220-x     Document Type: Article

References (38)

1. Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111:2962-2972
2. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860-1873
3. Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 28:830-834
4. Rajkumar SV (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8:479-491
5. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA et al (2011) Trends in allogeneic stem cell transplantation for multiple myeloma: a center for international blood and marrow transplant research (CIBMTR) analysis. Blood 118(7):1979-1988
6. Hall SL, Tate J, Gill D, Mollee P (2009) Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clin Biochem Rev 30:113-118
7. Sucak G, Suyani E, Ozkurt ZN, Yegin ZA, Aki Z et al (2010) Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance? Hematol Oncol 28:180-184
8. Maisnar V, Tichy M, Smolej L, Zak P, Radocha J et al (2007) Isotype class switching after transplantation in multiple myeloma. Neoplasma 54:225-228
9. Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL et al (2008) Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol 143:654-660
10. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D et al (1998) Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 91:3518-3523
11. de Larrea CF, Cibeira MT, Elena M, Arostegui JI, Rosinol L et al (2009) Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood 114:4954-4956
12. Alejandre ME, Madalena LB, Pavlovsky MA, Facio ML, Corrado C et al (2010) Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience. Clin Chem Lab Med 48:727-731
13. Bertinetti D, Schweinsberg S, Hanke SE, Schwede F, Bertinetti O et al (2009) Chemical tools selectively target components of the PKA system. BMC Chem Biol 9:3
14. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS (1999) Probability- based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551- 3567
15. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A et al (2003) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 31:365-370
16. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M et al (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117:4691-4695
17. Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3-9
18. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK et al (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244
19. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K et al (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28:1248-1250
20. Cappello F, Conway de Macario E, Marasa L, Zummo G, Macario AJ (2008) Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy. Cancer Biol Ther 7:801-809
21. Sherman M, Multhoff G (2007) Heat shock proteins in cancer. Ann N Y Acad Sci 1113:192-201
22. Fernandez de Larrea C, Tovar N, Cibeira MT, Arostegui JI, Rosinol L et al (2011) Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica 96:171-173
23. Anderson KS, LaBaer J (2005) The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4:1123- 1133
24. Caron M, Choquet-Kastylevsky G, Joubert-Caron R (2007) Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteom 6:1115-1122
25. Tan HT, Low J, Lim SG, Chung MC (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276:6880-6904
26. Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704- 2715
27. Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M (2002) Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 188:43-50
28. Zhou FL, Zhang WG, Chen G, Zhao WH, Cao XM et al (2006) Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma. Cancer Immunol Immunother 55:910-917
29. Zwick C, Preuss KD, Kubuschok B, Held G, Ahlgrimm M et al (2009) Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-Associated antigens. Ann Hematol 88:999-1003
30. Zwick C, Held G, Hammermeister V, Alahmad A, Kubuschok B et al (2009) Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas. J Cancer Res Clin Oncol 135:1207-1213
31. Huang S, Preuss KD, Xie X, Regitz E, Pfreundschuh M (2002) Analysis of the antibody repertoire of lymphoma patients. Cancer Immunol Immunother 51:655-662
32. Meklat F, Li Z, Wang Z, Zhang Y, Zhang J et al (2007) Cancertestis antigens in haematological malignancies. Br J Haematol 136:769-776
33. Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U et al (2007) STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 109:720-728
34. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF et al (2003) A high-Affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410
35. Cicconi R, Delpino A, Piselli P, Castelli M, Vismara D (2004) Expression of 60 kDa heat shock protein (Hsp60) on plasma membrane of Daudi cells. Mol Cell Biochem 259:1-7
36. Frisoni L, McPhie L, Colonna L, Sriram U, Monestier M et al (2005) Nuclear autoantigen translocation and autoantibody opsonization lead to increased dendritic cell phagocytosis and presentation of nuclear antigens: a novel pathogenic pathway for autoimmunity? J Immunol 175:2692-2701
37. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A et al (2009) An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-Associated antigen. Int J Cancer 125:639-648
38. Capello M, Ferri-Borgogno S, Cappello P, Novelli F (2011) alpha-Enolase: a promising therapeutic and diagnostic tumor target. FEBS J 278:1064-1074